Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin

References

• Peña SV, Hanson DA, Carr BA, Goralski TJ, Krensky AM. Processing, subcellular localization, and function of 519 (granulysin), a human late T cell activation molecule with homology to small, lytic, granule proteins. J Immunol. 1997;158:1–11.
   PubMed Web of Science ®Google Scholar
• Clayberger C, Finn MW, Wang T, Saini R, Wilson C, Barr VA, Sabatino M, Castiello L, Stroncek D, Krensky AM. 15 kDa granulysin causes differentiation of monocytes to dendritic cells but lacks cytotoxic activity. J Immunol. 2012;188:6119–6126. doi:10.4049/jimmunol.1200570.
   PubMed Web of Science ®Google Scholar
• Wei H, Lin L, Wang C, Lee Y, Chen Y, Antimicrobial LY. Properties of an immunomodulator – 15 kDa human granulysin. PLoS One. 2016;11:e0156321. doi:10.1371/journal.pone.0156321.
   PubMed Web of Science ®Google Scholar
• Lettau M, Dietz M, Dohmen K, Leippe M, Kabelitz D, Janssen O. Granulysin species segregate to different lysosome-related effector vesicles (LREV) and get mobilized by either classical or non-classical degranulation. Mol Immunol. 2019;107:44–53. doi:10.1016/j.molimm.2018.12.031.
   PubMed Web of Science ®Google Scholar
• Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, Thoma-Uszynski S, Melián A, Bogdan C, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science. 1998;282:121–125. doi:10.1126/science.282.5386.121.
   PubMed Web of Science ®Google Scholar
• Dotiwala F, Mulik S, Polidoro R, Ansara J, Burleigh B, Walch M, Gazzinelli RT, Lieberman J. Killer lymphocytes use granulysin, perforin and granzymes to kill intracellular parasites. Nature Med. 2016;22:210–216. doi:10.1038/nm.4023.
   PubMed Web of Science ®Google Scholar
• Walch M, Dotiwala F, Mulik S, Thiery J, Kirchhausen T, Clayberger C, Krensky AM, Martinvalet D, Lieberman J. Cytotoxic cells kill intracellular bacteria through granulysin-mediated delivery of granzymes. Cell. 2014;157:1309–1323. doi:10.1016/j.cell.2014.03.040.
   PubMed Web of Science ®Google Scholar
• Aporta A, Catalán E, Galán-Malo P, Ramírez-Labrada A, Pérez M, Azaceta G, Palomera L, Naval J, Marzo I, Pardo J, et al. Granulysin induces apoptotic cell death and cleavage of the autophagy regulator Atg5 in human hematological tumors. Biochem Pharmacol. 2014;87:410–423. doi:10.1016/j.bcp.2013.10.001.
   PubMed Web of Science ®Google Scholar
• Gamen S, Hanson DA, Kaspar A, Naval J, Krensky AM, Anel A. Granulysin-induced apoptosis. I. Involvement of at least two distinct pathways. J Immunol. 1998;161:1758–1764.
   PubMed Web of Science ®Google Scholar
• Pardo J, Pérez-Galán P, Gamen S, Marzo I, Monleón I, Kaspar AA, Susín SA, Kroemer G, Krensky AM, Naval J, Anel A. A role of the mitochondrial apoptosis-inducing factor (AIF) in granulysin-induced apoptosis. J Immunol. 2001;167:1222–1229. doi:10.4049/jimmunol.167.3.1222.
   PubMed Web of Science ®Google Scholar
• Al-Wasaby S, de Miguel D, Aporta A, Naval J, Conde B, Martínez-Lostao L, Anel A. In vivo potential of recombinant granulysin against human tumors. OncoImmunol. 2015;4:e1036213. doi:10.1080/2162402X.2015.1036213.
   PubMed Web of Science ®Google Scholar
• Martinez-Lostao L, de Miguel D, Al-Wasaby S, Gallego-Lleyda A, Anel A. Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities. Immunotherapy. 2015;7:883–892. doi:10.2217/imt.15.56.
   PubMed Web of Science ®Google Scholar
• Pastan I, Hassan R, Fitzgerald D, Kreitman R. Immunotoxin therapy of cancer. Naure Rev Cancer. 2006;6:559–565. doi:10.1038/nrc1891.
   PubMed Web of Science ®Google Scholar
• Chowdhury P, Viner J, Beers R, Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci USA. 1998;95:669–674. doi:10.1073/pnas.95.2.669.
   PubMed Web of Science ®Google Scholar
• Deckert P. Current constructs and targets in clinical development for antibody-based cancer therapy. Curr Drug Targets. 2009;10:158–175. doi:10.2174/138945009787354502.
   PubMed Web of Science ®Google Scholar
• Sanz L, Kristensen P, Blanco B, Facteau S, Russell S, Winter G, Alvarez-Vallina L. Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther. 2002;9:1049–1053. doi:10.1038/sj.gt.3301725.
   PubMed Web of Science ®Google Scholar
• Kreitman R, Stetler-Stevenso M, Jaffe E, Conlon K, Steinberg S, Wilson W, Waldmann TA, Pastan I. Complete remissions of adult T-cell leukemia with anti-CD25 recombinant immunotoxin LMB-2 and chemotherapy to block immunogenicity. Clin Cancer Res. 2016;22:310–318. doi:10.1158/1078-0432.CCR-15-1412.
   PubMed Web of Science ®Google Scholar
• Kreitman R, Tallman M, Robak T, Coutre S, Wilson W, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012;30:1822–1828. doi:10.1200/JCO.2011.38.1756.
   PubMed Web of Science ®Google Scholar
• Liu W, Onda M, Lee B, Kreitman R, Hassan R, Xiang L, Pastan I. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci USA. 2012;109:11782–11787.
   Web of Science ®Google Scholar
• Tomé-Amat J, Olombrada M, Ruiz-de-la-Herrán J, Pérez-Gómez E, Andradas C, Sánchez C, Martínez L, Martínez-del-Pozo A, Gavilanes JG, Lacadena J. Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin α-sarcin in nude mice bearing human colorectal cancer xenografts. SpringerPlus. 2015;4:168. doi:10.1186/s40064-015-0943-5.
   PubMedGoogle Scholar
• Kreitman R, Dearden C, Zinzani P, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018;32:1768–1777. doi:10.1038/s41375-018-0210-1.
   PubMed Web of Science ®Google Scholar
• Kowalski M, Guindon J, Brazas L, Moore C, Entwistle J, Cizeau J, Jewett MA, MacDonald GC. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin. J Urol. 2012;188:1712–1718. doi:10.1016/j.juro.2012.07.020.
   PubMed Web of Science ®Google Scholar
• Beauchemin N, Draber P, Dveksler G, Gold P, Gray-Owen S, Grunert F, Hammarström S, Holmes KV, Karlsson A, Kuroki M, et al. Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res. 1999;252:243–249. doi:10.1006/excr.1999.4610.
   PubMed Web of Science ®Google Scholar
• Gold P, Freedman S. Demonstration of tumor specific antigen in human colon carcinoma by immunological tolerance and absorption techniques. J Exp Med. 1965;121:439–462. doi:10.1084/jem.121.3.439.
   PubMed Web of Science ®Google Scholar
• Kammerer R, Zimmermann W. Coevolution of activating and inhibitory receptors within mammalian carcinoembryonic antigen families. BMC Biol. 2010;8:12. doi:10.1186/1741-7007-8-12.
   PubMed Web of Science ®Google Scholar
• Kuespert K, Pils S, Hauck C. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol. 2006;18:565–571.
   Web of Science ®Google Scholar
• Javaheri A, Kruse T, Moonens K, Mejías-Luque R, Debraekeleer A, Asche C, Tegtmeyer N, Kalali B, Bach NC, Sieber SA, et al. Helicobacter pylori adhesin HopQ engages in a virulence-enhancing interaction with human CEACAMs. Nature Microbiol. 2016;17:16189.
   Google Scholar
• Kinugasa T, Kuroki M, Yamanaka T, Matsuo Y, Oikawa S, Nakazato H, Matsuoka Y. Non-proteolytic release of carcinoembryonic antigen from normal human colonic epithelial cells cultured in collagen gel. Int J Cancer. 1994;58:102–107. doi:10.1002/ijc.2910580117.
   PubMed Web of Science ®Google Scholar
• Duffy M, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O. Clinical utility of biochemical markers in colorectal cancer: European group on tumour markers (EGTM) guidelines. Eur J Cancer. 2003;39:718–727.
   PubMed Web of Science ®Google Scholar
• Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother. 2009;32:341–352. doi:10.1097/CJI.0b013e31819b7c70.
   PubMed Web of Science ®Google Scholar
• Gilham D, O’Neil A, Hughes C, Guest R, Kirillova N, Lehane M, Hawkins RE. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother. 2002;25:139–151.
   PubMed Web of Science ®Google Scholar
• Begent R, Verhaar M, Chester K, Casey J, Green A, Napier M, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nature Med. 1996;2:979–984.
   PubMed Web of Science ®Google Scholar
• Boehm M, Corper A, Wan T, Sohi M, Sutton B, Thornton JD, Keep PA, Chester KA, Begent RH, Perkins SJ. Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J. 2000;346:519–528.
   PubMed Web of Science ®Google Scholar
• Verhaar M, Chester K, Keep P, Robson L, Pedley R, Boden J, Hawkins RE, Begent RH. A single chain Fv derived from a filamentous phage library has distinct tumor targeting advantages over one derived from a hybridoma. Int J Cancer. 1995;61:497–501. doi:10.1002/ijc.2910610412.
   PubMed Web of Science ®Google Scholar
• Blanco-Toribio A, Lacadena J, Nuñez-Prado N, Álvarez-Cienfuegos A, Villate M, Compte M, Sanz L, Blanco FJ, Álvarez-Vallina L. Efficient production of single-chain fragment variable-based N-terminal trimerbodies in Pichia pastoris. Microb Cell Fact. 2014;13:116. doi:10.1186/1475-2859-13-1.
   PubMed Web of Science ®Google Scholar
• Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res. 2016;22:3286–3297. doi:10.1158/1078-0432.CCR-15-1696.
   PubMed Web of Science ®Google Scholar
• Cuesta A, Sánchez-Martín D, Sanz L, Bonet J, Compte M, Kremer L, Blanco FJ, Oliva B, Alvarez-Vallina L. In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences. PLoS One. 2009;4:e5381. doi:10.1371/journal.pone.0005381.
   PubMed Web of Science ®Google Scholar
• Daly R, Hearn M. Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production. J Mol Recognit. 2005;18:119–138. doi:10.1002/jmr.687.
   PubMed Web of Science ®Google Scholar
• Mazor R, Onda M, Pastan I. Immunogenicity of therapeutic recombinant immunotoxins. Immunol Rev. 2016;270:152–164. doi:10.1111/imr.12390.
   PubMed Web of Science ®Google Scholar
• Mazor R, King E, Pastan I. Strategies to reduce the immunogenicity of recombinant immunotoxins. Am J Pathol. 2018;188:1736–1743. doi:10.1016/j.ajpath.2018.04.016.
   PubMed Web of Science ®Google Scholar
• Mathew M, Verma R. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci. 2009;100:1359–1365. doi:10.1111/j.1349-7006.2009.01192.x.
   PubMed Web of Science ®Google Scholar
• Hlongwane P, Mungra N, Madheswaran S, Akinrinmade O, Chetty S, Barth S. Human granzyme B based targeted cytolytic fusion proteins. Biomedicines. 2018;6:E72. doi:10.3390/biomedicines6020072.
   PubMed Web of Science ®Google Scholar
• Chester K, Pedley B, Tolner B, Violet J, Mayer A, Sharma S, Boxer G, Green A, Nagl S, Begent RH. Engineering antibodies for clinical applications in cancer. Tumor Biol. 2004;25:91–98. doi:10.1159/000077727.
   PubMed Web of Science ®Google Scholar
• Boxer G, Stuart-Smith S, Flynn A, Green A, Begent R. Radioimmunoluminography: a tool for relating tissue antigen concentration to clinical outcome. Br J Cancer. 1999;80:922–926. doi:10.1038/sj.bjc.6690443.
   PubMed Web of Science ®Google Scholar
• Cuesta A, Sánchez-Martín D, Blanco-Toribio A, Villate M, Enciso-Álvarez K, Alvarez-Cienfuegos A, Sainz-Pastor N, Sanz L, Blanco FJ, Alvarez-Vallina L. Improved stability of multivalent antibodies containing the human collagen XV trimerization domain. MAbs. 2012;4:226–232. doi:10.4161/mabs.4.2.19140.
   PubMed Web of Science ®Google Scholar
• Weidner M, Taupp M, Hallam S. Expression of recombinant proteins in the methylotrophic yeast Pichia pastoris. J Vis Exp. 2010;36:e1862.
   PubMedGoogle Scholar
• Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine D, Abbot BJ, Mayo JG, Shoemaker RH, Boyd MR. Sensibility of drug screening with panels of human tumor cell lines using microculture tetrazolium assay. Cancer Res. 1988;48:589–601.
   PubMed Web of Science ®Google Scholar